Frontotemporal disorders, most commonly known as Pick’s disease, are damage to the nerve cells in specific area of brain that is frontal and temporal lobes. Frontotemporal disorders lead to dementia which alter the identity, conduct, dialect and development of muscles. Due to frontotemporal disorders, numerous conceivable indications may result, including strange practices, emotional issues, difficulty in working, or trouble with strolling. Frontotemporal degenerations are mainly caused due to group of brain disorders which involves protein tau and protein TDP43 which directly attack on the frontal and temporal lobes of the brain. Frontotemporal disorders is mainly subdivided into three types, Behavior Variant Frontotemporal Dementia (bvFTD), Primary progressive aphasia (PPA), and Disturbances of motor (movement or muscle) function. There is no curable treatment for frontotemporal disorders but certain medications can help in reducing the disturbance, peevishness as well as despondency.
The global frontotemporal disorders treatment market is segmented on the basis of medication, type of disease and end user. On the basis of medication, the global frontotemporal disorders treatment market is segmented into antidepressants and antipsychotics. Antidepressants are mainly prescribed as depression and anxiety are main symptoms of frontotemporal disorders treatment market. On the basis of type of disease, the global frontotemporal disorders treatment market is segmented into behavior variant frontotemporal dementia, primary progressive aphasia, and disturbances of motor function. PPA is further segmented into nonfluent variant of PPA and semantic variant of PPA. On the basis of end user, the global frontotemporal disorders treatment market is segmented into hospitals, specialty clinics, and nursing homes.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5033
Some of the key players competing in the global Frontotemporal Disorders Treatment Market are Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, and Pfizer, among others. Many new strategies including R&D investments, geographic expansion and competitive pricing policies adapted by players had helped to increase the global Frontotemporal Disorders Treatment Market.